Target F7BIV4 is the selected 516-residue horse protein. Pairwise sequence analysis covers all 501 residues of human Q12933 with 92.0% paired identity; the RING/zinc-finger and C-terminal TRAF architecture is retained. The insertion after aligned human position 265 does not remove a major domain. Pairwise similarity is not a reciprocal-orthology analysis, and the current sequence has not been verified against the original ProtNLM input.
Primary human/mouse evidence supports all five ProtNLM terms: T-cell cytokine production (PMID:15125833), direct CD40 binding (PMID:9718306), cIAP-associated ligase-complex and TNF-receptor-complex membership (PMID:20447407), and broad immunoglobulin regulation through CD40 (PMID:17360936 with direct human receptor-binding evidence). These are explicitly mammalian transfers, not horse experiments. The last claim does not establish every isotype or species-specific response. COR means the supported term is absent from the frozen horse GOA; training membership is unknown.
The existing electronic E3 and autoubiquitination assertions remain UNDECIDED because human primary studies provide conflicting mechanistic evidence (PMID:19810754 versus PMID:20577214). TRAF2 recruitment of catalytic cIAPs is independently supported and is sufficient for ligase-complex membership. No ARBA assertion or AI-generated review prose is used as biological validation. The unreviewed horse record and absence of identified horse-specific mechanistic literature did not justify a horse Edison job; human manual research supplies the detailed investigation.